Adgero Biopharmaceuticals Holdings, Inc. Contracts & Agreements
45 Contracts & Agreements
- Business Finance (26 contracts)
- Business Operations (3)
- Human Resources (11)
- Mergers & Acquisitions (1)
- Real Estate (2)
- Uncategorized (2)
- Second Amendment to Registration Rights Agreement (Filed With SEC on October 17, 2017)
- Employment Agreement, dated October 11, 2017, between the Company and John Liatos (Filed With SEC on October 17, 2017)
- Warrant Agent Agreement, dated August 14, 2017, between the Company and Aegis Capital Corp (Filed With SEC on October 17, 2017)
- Employment Agreement, dated September 1, 2017, between the Company and Felix Garzon (Filed With SEC on October 17, 2017)
- FIRST AMENDMENT TO THE ADGERO BIOPHARMACEUTICALS HOLDINGS, INC. 2016 EQUITY INCENTIVEPLAN (Filed With SEC on April 11, 2017)
- AGREEMENT AND PLAN OF MERGER by and among ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., ADGERO ACQUISITION, INC., ADGEROBIOPHARMACEUTICALS,INC. and FRANK G. PILKIEWICZ, as the... (Filed With SEC on February 14, 2017)
- Form of Replacement Warrant (Filed With SEC on February 14, 2017)
- Form of Investor Warrant (Filed With SEC on February 14, 2017)
- Form of Placement Agent Warrant (Filed With SEC on February 14, 2017)
- Registration Rights Agreement (Filed With SEC on February 14, 2017)
- Form of August Investor Warrant (Filed With SEC on February 14, 2017)
- Form of Common Stock Certificate (Filed With SEC on February 14, 2017)
- Form of December 2016 Investor Warrant (Filed With SEC on February 14, 2017)
- Placement Agency Agreement, dated January 11, 2016, between the Company and Aegis Capital Corp (Filed With SEC on February 14, 2017)
- Form of Subscription Agreement for the Companys 2016 private placement (Filed With SEC on February 14, 2017)
- Form of Voting Agreement, dated April 8, 2016, by and among the Company and the stockholders named therein (Filed With SEC on February 14, 2017)
- 2016 Equity Incentive Plan (Filed With SEC on February 14, 2017)
- Form of Incentive Stock Option Agreement (Filed With SEC on February 14, 2017)
- Form of Non-Qualified Stock Option Agreement (Filed With SEC on February 14, 2017)
- Form of Restricted Stock Agreement (Filed With SEC on February 14, 2017)
- Employment Agreement, dated April 8, 2016, between the Company and Frank Pilkiewicz, PhD (Filed With SEC on February 14, 2017)
- Employment Agreement, dated April 8, 2016, between the Company and Steven Rychnovsky, PhD (Filed With SEC on February 14, 2017)
- Form of Subscription Agreement for the Companys August private placement (Filed With SEC on February 14, 2017)
- Promissory Note, dated July 9, 2014, among Adgero Biopharmaceuticals, Inc. and Frank Pilkiewicz, PhD (Filed With SEC on February 14, 2017)
- Amendment to Promissory Note, dated December 30, 2015, among Adgero Biopharmaceuticals, Inc. and Frank Pilkiewicz, PhD (Filed With SEC on February 14, 2017)
- Asset Purchase Agreement, dated as of November 26, 2012, among Adgero Biopharmaceuticals, Inc. and St. Cloud Investments, LLC (Filed With SEC on February 14, 2017)
- Amendment to Asset Purchase Agreement, dated May 12, 2014, among Adgero Biopharmaceuticals, Inc. and St. Cloud Investments, LLC (Filed With SEC on February 14, 2017)
- 6% Convertible Note, dated October 6, 2015, among Adgero Biopharmaceuticals, Inc. and Robert F. Hendrickson (Filed With SEC on February 14, 2017)
- Amendment to 6% Convertible Note, dated March 25, 2016, among Adgero Biopharmaceuticals, Inc. and Robert F. Hendrickson (Filed With SEC on February 14, 2017)
- 6% Convertible Note, dated October 28, 2015, among Adgero Biopharmaceuticals, Inc. and Roman Perez-Soler, MD (Filed With SEC on February 14, 2017)
- Amendment to 6% Convertible Note, dated March 28, 2016, among Adgero Biopharmaceuticals, Inc. and Roman Perez-Soler, MD (Filed With SEC on February 14, 2017)
- 6% Convertible Note, dated December 23, 2015, among Adgero Biopharmaceuticals, Inc. and Adam Stern (Filed With SEC on February 14, 2017)
- Amendment to 6% Convertible Note, dated March 21, 2016, among Adgero Biopharmaceuticals, Inc. and Adam Stern (Filed With SEC on February 14, 2017)
- Engagement Letter, dated August 8, 2016, between the Company and Aegis Capital Corporation (Filed With SEC on February 14, 2017)
- 8% Convertible Note, dated November 26, 2012, among Adgero Biopharmaceuticals, Inc. and St. Cloud Investments, LLC (Filed With SEC on February 14, 2017)
- 8% Convertible Note, dated November 26, 2012, among Adgero Biopharmaceuticals, Inc. and Steven Rychnovsky, PhD (Filed With SEC on February 14, 2017)
- Form of Indemnification Agreement (Filed With SEC on February 14, 2017)
- Employment Agreement, dated October 3, 2016, between the Company and Laura Pflug (Filed With SEC on February 14, 2017)
- Agreement of Lease, dated November 8, 2016, between the Company and Sutman Princeton Associates, L.P (Filed With SEC on February 14, 2017)
- Lease Modification Agreement, dated November 8, 2016, between the Company and Sutman Princeton Associates, L.P (Filed With SEC on February 14, 2017)
- Employment Agreement, dated April 8, 2016, between the Company and Jane Maida (Filed With SEC on February 14, 2017)
- Amendment No. 1 to Employment Agreement, dated February 8, 2017, between the Company and Frank Pilkiewicz, PhD (Filed With SEC on February 14, 2017)
- Amendment No. 1 to Employment Agreement, dated February 8, 2017, between the Company and Steven Rychnovsky, PhD (Filed With SEC on February 14, 2017)
- Amendment No. 1 to Employment Agreement, dated February 8, 2017, between the Company and Laura Pflug (Filed With SEC on February 14, 2017)
- Form of Subscription Agreement for the Company's December 2016 Private Placement (Filed With SEC on February 14, 2017)